分子生物学
IVD分子诊断
细胞培养与分析
蛋白研究
细胞因子
重组蛋白
抗体
高通量测序建库
病原检测UCF系列
生物医药
工具酶
抑制剂激活剂与常用试剂
仪器
耗材

The PLAU-ITGB1-TGF-β axis orchestrates spatiotemporal reprogramming of fibroblasts at the invasive front to drive dual immunosuppressive niche and immunotherapy resistance in oral squamous cell carcinoma

Xiong Yili, Liu Shaopeng, Zhao Lianyu, Liu Xinze, Zhang Hanzhi, Wang Haoran, Zhang Dongsheng, Wang Changlong, Wu Haiwei

Journal:Cell Death & Disease

IF:12.2

DOI:10.1038/s41419-026-09110-4

PMID:42463632

Published:2026-07-16

research field:可持续工程聚合物化学复合材料材料科学绿色化学

Abstract

The initiation and progression of cancer are driven by the dynamic interplay between somatic mutations and the tumor microenvironment. Identifying core cell populations driving malignant transformation and understanding the intercellular interactions within the tumor microenvironment are, therefore, crucial for early diagnosis and effective treatment. Here, we construct a spatiotemporal atlas of oral squamous cell carcinoma (OSCC) progression by integrating multi-omics approaches. Our analysis reveals that the critical driver gene PLAU activates the TGF-β pathway via ITGB1, thereby promoting the conversion of fibroblasts into the COL11A1⁺ fibroblast (COL11A1⁺ Fib). These specialized fibroblasts remodel the extracellular matrix (ECM), collectively establishing an immunosuppressive niche composed of malignant epithelial cells, COL11A1 + Fib, and regulatory T cells (Tregs). Importantly, targeting COL11A1 + Fib alleviates this immunosuppressive niche and curbs OSCC progression. Our findings underscore the potential of COL11A1 + Fib as a predictive biomarker, especially in combination with immunotherapy. Collectively, this work demonstrates that the PLAU-ITGB1-TGF-β axis drives the formation of an Epi-COL11A1 + Fib-Treg immunosuppressive niche that fuels OSCC malignancy.

本文使用的Yeasen产品

购物车
客服
转染试用